Published: October 2023
Top antibody discovery companies have been meticulously selected based on a proprietary antibody discovery platforms competitiveness analysis, taking into consideration technology portfolio strength and recent initiatives. These companies are playing important role in providing efficient antibody drug discovery services We analyzed a comprehensive list of antibody discovery companies that claim to offer innovative antibody discovery platforms. In this article, discover 9 leading antibody CRO and their capabilities in this industry.
In the cutting-edge field of biomedical science, the practice of antibody discovery underscores the importance of our body's immune response. Antibodies, also known as immunoglobulins, are Y-shaped glycoproteins that serve as the vanguard of our immune system. They counteract foreign molecules or antigens that intrude into our body, ranging from viruses, fungi, and bacteria to non-living substances, such as toxins and chemicals. The intricacies of the antibody discovery process entail recognizing a unique region on an antigen, termed as an epitope, to which antibodies can bind and mediate an immune response. This opsonization process facilitates the phagocytosis of foreign substances, effectively neutralizing potential threats. In recent times, there has been a palpable surge in the antibody discovery market, driven predominantly by the rising demand for antibody therapeutics. Consequently, the landscape of antibody discovery services has undergone significant changes with companies increasingly outsourcing to CMOs and CDMOs. These organizations, including notable antibody discovery companies like Myrio Therapeutics, have been deploying innovative antibody discovery platforms to accelerate workflow and offer specialized services. Their expertise ranges from antibody drug discovery services to more comprehensive antibody CRO services. These advances are not only ensuring more efficient antibody solutions but also contributing to the growth and dynamism of the antibody discovery market. Further, antibody discovery companies like Mabsilico are employing computational approaches to revolutionize the antibody discovery platform. Their services are designed to expedite and streamline the antibody discovery process. Together with other leading players in the field, they are reshaping the future of antibody drug discovery services.
Looking ahead, the antibody discovery market is poised for significant growth. The market size is expected to expand at a 12% CAGR during the forecast period of 2023-2035. This growth is anticipated to be driven by the increasing demand for custom antibody services, including custom antibody development and antibody characterization services. The global market is set to witness this surge, with North America leading the charge due to its advanced healthcare infrastructure and high investment in research and development. Market report indicates that antibody discovery companies, including AlivaMab Discovery Services and Abveris are making substantial contributions to this growth through their innovative approaches to antibody discovery. Roots Analysis has conducted an exhaustive study on Antibody Discovery Market featuring the current market landscape, market size and future opportunity for the antibody discovery companies, over a span of 12 years.
As the antibody discovery market continues to expand, with North America as a prominent hub of antibody discovery services, the partnership between antibody drug developers and antibody discovery companies will play a pivotal role in catalyzing market growth and shaping the future of antibody discovery process for different types of antibodies, including, bispecific antibodies, antibody drug conjugates and other novel antibody therapies.
The top antibody discovery companies offering antibody discovery platforms are listed below (in alphabetical order):
1. Ablexis
2. Creative Biolabs
3. Genmab
4. Harbour BioMed
5. Immunome
6. Isogenica
7. Kymab
8. Ligand Pharmaceuticals
9. MorphoSys
Interested in exploring all antibody discovery companies, their antibody discovery services and antibody discovery platforms?
This article highlights the top 9 antibody discovery companies offering antibody discovery platforms to watch out for in this industry. These companies were chosen based on Roots Analysis’ proprietary antibody discovery platforms competitiveness analysis, taking into consideration technology portfolio strength and recent initiatives. It is essential to note that the selection of top players can differ substantially according to the defined criteria(s).
 |
Ablexis is US-based pharmaceutical company engaged in the generation of therapeutic antibody candidates with high potency, specificity, solubility and low immunogenicity risks, using its proprietary AlivaMab Mouse technology. As per the firm’s website, its platform allows for rapid discovery of high-quality therapeutic lead candidates over other antibody discovery platforms. In addition, it is worth highlighting that, the company has licensed its technology to several pharmaceutical and biotechnology companies.
Antibody Discovery Platforms Portfolio
| Platform | Method of Antibody Generation | Types of Antibodies Generated |
| AlivaMab Mouse | Transgenic Animal-based |
|
Recent Developments:
In February 2023, Ablexis entered into a licensing agreement with Adimab in order to incorporate AlivaMab Mouse technology for antibody discovery process.1 Earlier, in November 2022, Ablexis and AlivaMab Discovery Services announced the expansion of capabilities related to antibody drug discovery and engineering. The expanded capabilities consist of diverse panels of high-quality antibodies that can be reformatted into multispecific formats as per partner’s choice. The panels include a large selection of CD3 antibodies that engage T-cells and eliminate cancer cells with minimal cytokine release.
 |
Creative Biolabs is a biotechnology company engaged in the production and engineering of antibodies. The company utilizes its broad range of proprietary technologies, such as phage display platform, Hyperdoma, Fully Human Antibody Technology (FHAT), B-cell sorting platform, Magic Platform, Hi-affi Human Antibody Discovery Platform, Multiple Epitopes Antigen Designer (MEAD) and Native Antibody Discovery Platform for the generation of a large panel of antibodies. In addition, the company offers a wide array of services ranging from antigen designing to antibody optimization.
Antibody Discovery Platforms Portfolio
| S.No. | Platform | Method of Antibody Generation | Types of Antibodies Generated |
| 1 | B-cell Sorting Platform | Single cell-based |
|
| 2 | Fully Human Antibody Technology | Transgenic Mouse |
|
| 3 | Hi-Affi | Others |
|
| 4 | Hyperdoma | Hybridoma Technology |
|
| 5 | Magic (Membrane Protein Production Platform) | Others |
|
| 6 | MEAD (Multiple Epitopes Antigen Designer) | Hybridoma Technology |
|
| 7 | Native Antibody Discovery Platform | Single cell-based |
|
| 8 | Phage Display Platform | Phage Display |
|
Recent Developments:
In October 2023, company attended following conferences:
 |
Genmab is a biotechnology company that specializes in the discovery and development of differentiated antibody therapeutics for cancer. The company utilizes its proprietary platform for generation of large panels of antibodies. In addition, the company is engaged in building its own pipeline of molecules by innovative scientific approach, expertise in translational medicine laboratory and forming strategic partnerships.
Antibody Discovery Platforms Portfolio
| Platform | Method of Antibody Generation | Types of Antibodies Generated |
| DuoBody | Others |
|
Recent Developments: In April 2023, the company entered into an agreement with Argenx in order to co-develop and commercialize antibody drug candidates for the treatment of immunology and oncology disorders.2
 |
Harbour BioMed is a biotechnology company that specializes in the discovery and development of novel therapeutics for cancer, specifically in the field of immuno-oncology. Its business operations are based in Cambridge, Massachusetts, US and its antibody platform segment is located in Rotterdam, the Netherlands. The discovery and development programs of the company are centered on its two patented transgenic mouse platforms for the discovery of human antibodies. The company is involved in building its own pipeline of molecules by internal discovery and development efforts, forming collaborative alliances or through acquisitions of selective preclinical and clinical stage assets. Further, the company provides access to its platforms to other companies and academic institutes through its subsidiary, Harbour Antibodies.
Antibody Discovery Platforms Portfolio
| S.No. | Platform | Method of Antibody Generation | Types of Antibodies Generated |
| 1 | Harbour Mice | Transgenic Animal Based |
|
| 2 | HBICE | Others |
|
| 3 | HCAbs platform | Transgenic Animal Based |
|
Recent Developments: In November 2022, the company entered into a licensing agreement with Moderna in order to discover and develop antibodies for oncological targets.3 Earlier, in October 2022, the company entered into an agreement with CSPC Pharmaceutical in order to develop and commercialize Batoclimab (HBM9161) in Greater China and in April 2022, it inked partnership with AstraZeneca in order to out-license a CLDN18.2xCD3 targeting bispecific antibody, HBM7022.
 |
Immunome is a biotechnology company that specializes in the discovery and development of novel antibody therapeutics, with a focus on oncology and infectious diseases. It is important to mention that the company is building a rich pipeline of novel antibodies through its Immunome Discovery Engine. In addition, the company examines human B cell to produce vast quantities of antibodies for functional based screening. The company claims that it has created over 250,000 hybridomas from cancer patients and patients suffering from a variety of malignancies and infectious diseases.
Antibody Discovery Platforms Portfolio
| Platform | Method of Antibody Generation | Types of Antibodies Generated |
| RealMab | Hybridoma Based Single B-cell Based |
Bispecific Antibodies Antibody Drug Conjugates |
| ScreenMab | NA | NA |
Recent Developments: In June 2023, Immunome and Morphimmune announced a definitive merger agreement and a simultaneous private placement investment of USD 125 million to develop targeted cancer therapies. The combined company, operating as Immunome, will have a synergistic platform to develop best-in-class targeted cancer therapies across multiple modalities.4
 |
Isogenica is a biotechnology company that specializes in generation of biotherapeutics for the treatment of various diseases, such as cancer, inflammation, and other diseases. It is important to mention that the company utilizes its proprietary technologies, namely Alexandria and LlamdA VHH library or the generation of large panels of antibodies, such as single domain, monoclonal, bispecific antibodies and antibody drug conjugates. In addition, the company is involved in building its own pipeline of molecules by internal discovery and development efforts, partnering with global biopharmaceutical companies or through acquisitions of selective preclinical and clinical stage assets.
Antibody Discovery Platforms Portfolio
| S.No | Platform | Method of Antibody Generation | Types of Antibodies Generated |
| 1 | Alexandria | Phage Display Based |
|
| 2 | llamdA | Phage Display Based |
|
Recent Developments: In March 2023, the company entered into an agreement with Frederick National Laboratory for Cancer Research in order to develop multiple molecules for the purpose of measuring biomarkers.5 Earlier, in January 2023, the company signed a technology licensing agreement with Arvinas in order to employ former company’s CIS Display technology.
 |
Ligand Pharmaceuticals is a biopharmaceutical company that focuses on drug discovery, early-stage drug development and product reformulation. In addition to building its own pipeline of molecules, the company has acquired various technologies to develop new molecules and help other pharmaceutical companies in the discovery and development of proprietary therapeutic molecules; these include (in alphabetical order) Captisol Technology, OmniAb Technology, HepDirect, LTP Technology and SUREtechnology Platform. Currently, the company claims to have licensed over 160 programs in various stages of commercialization and development.
Antibody Discovery Platforms Portfolio
| Platform | Method of Antibody Generation | Types of Antibodies Generated |
| OmniAb | Transgenic Animal Based |
|
Recent Developments: In September 2023, the company announced the acquisition of Novan for USD 12.2 million, including berdazimer gel and all assets related to the NITRICIL™ technology platform, and the rights to the Bayer-partnered Sitavig program.6
 |
Kymab is a biopharmaceutical company which is involved in the discovery and development of monoclonal / bispecific antibodies against difficult and novel drug targets, with the help of its proprietary transgenic mouse platform (Kymouse). It is building a rich pipeline of novel monoclonal / bispecific antibodies to target four disease areas, namely immuno-oncology, inflammation, hematology and infectious diseases. Additionally, the company is collaborating with other companies for the development of novel therapeutic antibodies. In addition to the development of its pipeline drugs from its proprietary platforms, the company provides access to its technology platforms by entering into licensing agreements with other companies.
Antibody Discovery Platforms Portfolio
| Platform | Method of Antibody Generation | Types of Antibodies Generated |
| IntelliSelect | Transgenic Animal Based |
|
| Kymouse | Transgenic Animal Based |
|
Recent Developments: In April 2021, Kymab was acquired by Sanofi. The acquisition aligns with the company's strategy to pursue best-in-class treatments in defined areas and builds on its leading presence in immunology.7
 |
MorphoSys is a German biopharmaceutical firm engaged in discovery, development, and commercialization of innovative therapies. The company offers its unique technologies, Ylanthia and HuCAL for the development of fully human antibodies. The antibodies generated using these technologies have numerous therapeutic and diagnostic applications. It is also worth mentioning that the company has entered into a number of partnerships, contributing to the development of more than 100 drug candidates.
Antibody Discovery Platforms Portfolio
| S.No | Platform | Method of Antibody Generation | Types of Antibodies Generated |
| 1 | IntelliSelect | Transgenic Animal Based |
|
| 2 | Kymouse | Transgenic Animal Based |
|
Recent Developments: In September 2023, the company announced that its investigational next-generation dual inhibitor of EZH2 and EZH1, tulmimetostat, has received fast track designation from the FDA for the treatment of patients with advanced, recurrent, or metastatic endometrial cancer harboring ARID1A mutations and who have progressed on at least one prior line of treatment.8
The above presentation features ten promising players from a pool of around 200 antibody discovery companies that we have compiled, offering antibody discovery platforms. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.
Ronit Sharma is an accomplished business research and competitive intelligence professional with over six years of experience in the pharmaceutical and healthcare industry. As a team leader at Roots Analysis, he has authored numerous multidisciplinary market research reports, and led the efforts on several bespoken consulting assignments, providing valuable insights into the latest innovations in healthcare and the digital transformation of the pharmaceutical industry. Ronit's exceptional analytical skills and strategic thinking in the field contribute to the firm's intellectual capital, empowering clients to make informed decisions in the dynamic pharmaceutical landscape. With a passion for staying at the forefront of industry advancements, Ronit specializes in identifying emerging opportunities for various stakeholders, leveraging his deep understanding of market trends and technological developments. He is committed to fostering an environment of excellence, creativity, and innovation within his team, encouraging collaboration and empowering team members to bring their best ideas to the table.
Recently, Ronit's expertise has been recognized by the online news agency, where he was interviewed and featured as an emerging industry leader. Ronit holds a B. Tech degree in Biotechnology from Lovely Professional University and his research and thought leadership can be found in his professional blog and social media profiles, where he shares the latest insights and engages in meaningful discussions with industry peers. To ensure the highest ethical standards, Ronit openly declares no conflicts of interest in his work, ensuring unbiased and trustworthy contributions. His insights undergo rigorous editorial and peer-review processes, establishing his credibility as a thought leader within the pharmaceutical and healthcare domain. Ronit's exceptional analytical and strategic thinking skills, coupled with his commitment to excellence, make him a valuable asset to any organization in the pharmaceutical and healthcare industry.
Email: ronit.sharma@rootsanalysis.com
LinkedIn: https://www.linkedin.com/in/ron001/
Sources:1 https://www.businesswire.com/news/home/20230209005161/en/Ablexis-Announces-License-Agreement-with-Adimab
Sources:2 https://ir.genmab.com/news-releases/news-release-details/genmab-and-argenx-enter-partnership-advance-antibody-therapies
Sources:3 https://www.harbourbiomed.com/news/196.html
Sources:4 https://investors.immunome.com/immunome-and-morphimmune-announce-definitive-merger-agreement-and-simultaneous-private-placement-investment-of-125-million-to-develop-targeted-cancer-therapies/
Sources:5 https://isogenica.com/isogenica-and-frederick-national-laboratory-for-cancer-research-add-two-more-projects-to-their-contractual-relationship/
Sources:6 https://investor.ligand.com/press-releases/detail/496/ligand-acquires-assets-of-novan-inc-for-12-2-million/
Sources:7 https://www.sanofi.com/en/media-room/press-releases/2021/2021-04-09-05-00-00-2207173/
Sources:8 https://www.morphosys.com/sites/morphosys-de/files/2023-09/230912_Tulmimetostat%20FDA%20EC%20FTD%20Press%20Release.pdf
MEDIA CITATIONS
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES
.png)
